Dr. Albert Chang
BoLAA 2022
“We’re honored to include Dr. Albert Chang into our BoLAA family.” ~Aurora DeRose
LOS ANGELES, CA, UNITED STATES, September 9, 2022 /EINPresswire.com/ — Dr. Albert Chang, Acclaimed UCLA Radiation Oncologist, wins Best of Los Angeles Award- “100 MOST FASCINATING PEOPLE IN LOS ANGELES – 2022”, in accordance with Aurora DeRose, award coordinator for the Best of Los Angeles Award group.
The “Best of Los Angeles Award” group was fashioned eight years in the past and consists of over 7,600 skilled members residing and dealing in Southern California. It celebrates the most effective individuals, locations and issues in Los Angeles with a slogan “No Ads. No B.S. Only the Best.”
“The mission of the community is to celebrate the best of Los Angeles, and allow its community members to connect with other members who share the highest standards of quality and integrity,” expresses DeRose. “We’re honored to include Dr. Albert Chang into our BoLAA family.”
Dr. Albert Chang, Associate Professor, is the Vice Chair of Surgical Services and Brachytherapy Service Chief for the Department of Radiation Oncology on the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center. Dr. Chang obtained his PhD in Molecular Medicine and MD levels from the Boston University School of Medicine. He accomplished his residency on the Washington University School of Medicine after which joined the school on the University of California, San Francisco as an Assistant Professor.
His medical focus is on malignancies of the genitourinary and gynecological techniques and focuses on excessive dose fee (HDR) brachytherapy. HDR brachytherapy is a extremely efficient modality for the supply of excessive, ablative doses of radiation instantly into tumors with the best conformality. This remedy modality requires ability and expertise. Dr. Chang has carried out over 1500 brachytherapy procedures.
Dr. Chang is thought internationally and has been invited to talk at scientific conferences globally. He has revealed quite a few peer-reviewed manuscripts and e book chapters and in addition serves on the Radiation Oncology Genitourinary Examination Committee of the American Board of Radiology. Dr. Chang’s analysis explores the use of novel systemic remedy mixtures with radiation remedy and the use of novel imaging applied sciences to enhance the supply of radiation. He has served because the principal investigator for medical trials together with the “Phase II Trial of Dose Escalated Radiotherapy with Leuprolide and Enzalutamide in Patients with Very High Risk or Pelvic Node Positive Prostate Cancer,” sponsored by the National Comprehensive Cancer Network. He can be the IMRT co-chair on the RTOG 0924 Phase III Study of Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer. He was awarded the Young Investigator Award by the Prostate Cancer Foundation for learning the underlying mechanisms for response and resistance in sufferers with oligometastatic prostate most cancers receiving radiation remedy with immunotherapy.
Aurora DeRose
Boundless Media Inc.
9518700099 ext.
e-mail us right here
